Results 151 to 160 of about 188,451 (293)

Role of Age and Sex on the Incidence of Leukemia in a Sample of Iraqi Patients

Medical Journal of Babylon
Background: Leukemia accounts for 8% of the total cancers in the population and is known as the world’s fifth most common type. Leukemia is not just a pediatric disease as most people assume. The disease consists of four main types and several sub-types,
Dahlia N. AL-Saidi
doaj   +1 more source

Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia [PDF]

, 1990
M Hauch, Gazzola Mv, Trudy N. Small, Claudio Bordignon, L Barnett, Isabel Cunningham, H Castro- Malaspinia, RJ O’Reilly, CA Keever   +8 more
openalex   +1 more source

The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.

Blood, 2015
A. J. Barrett, S. Ito
semanticscholar   +1 more source

NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia. [PDF]

Oncol Rep, 2023
Wang X, Rong S, Sun Y, Yin B, Yang X, Lu X, Sun H, Yan Y, Sun G, Liang Y, Wang P, Xie S, Li Y.   +12 more
europepmc   +1 more source

Bosutinib in the management of chronic myelogenous leukemia

Biologics: Targets & Therapy, 2013
Gunhild Keller-von Amsberg, Philippe SchafhausenDepartment of Hematology and Oncology and, Stem Cell Transplantation and Pulmonology Division, Oncological Center, University Hospital Hamburg-Eppendorf, Hamburg, GermanyAbstract: Bosutinib (SKI-606) is an ...
Keller-von Amsberg G, Schafhausen P
doaj  

Chronic myelogenous leukemia presenting with Morel Lavallée lesion: A case report of a rare presentation. [PDF]

Clin Case Rep, 2022
Mohamed SSI, Qasim HM, Mahfouz A, Osman MA, Ahmed AOE, Al-Azewi SH, Yassin MA, Fareed S.   +7 more
europepmc   +1 more source

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

Blood, 2002
C. Sawyers, A. Hochhaus, E. Feldman, J. Goldman, Carole B. Miller, O. Ottmann, C. Schiffer, M. Talpaz, F. Guilhot, M. Deininger, T. Fischer, S. O’Brien, R. Stone, C. Gambacorti-Passerini, N. Russell, J. Reiffers, T. Shea, B. Chapuis, S. Coutre, S. Tura, E. Morra, R. Larson, A. Saven, C. Peschel, A. Gratwohl, F. Mandelli, M. Ben-Am, I. Gathmann, R. Capdeville, R. Paquette, B. Druker   +30 more
semanticscholar   +1 more source

Severe tumor lysis syndrome during treatment with STI 571in a patient with chronic myelogenous leukemia accelerated phase [PDF]

, 2002
Amish Vora, Manisha Bhutani, Atul Sharma, V. Raina   +3 more
openalex   +1 more source

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Journal of Clinical Oncology, 2014
P. Rousselot, A. Charbonnier, P. Cony-Makhoul, P. Agapé, F. Nicolini, B. Varet, M. Gardembas, G. Étienne, D. Réa, L. Roy, M. Escoffre-barbe, A. Guerci-Bresler, M. Tulliez, S. Prost, M. Spentchian, J. Cayuela, J. Reiffers, J. Chomel, A. Turhan, J. Guilhot, F. Guilhot, F. Mahon   +21 more
semanticscholar   +1 more source

DNA self-assembly nanoflower reverse P-glycoprotein mediated drug resistance in chronic myelogenous leukemia therapy. [PDF]

Front Bioeng Biotechnol, 2023
Zhao P, Zhong Y, Pan P, Zhang S, Tian Y, Zhang J, Yi G, Zhao Z, Wu T.   +8 more
europepmc   +1 more source